Please login to the form below

Not currently logged in
Email:
Password:

Zontivity

This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer backs approval of TMC's cangrelor

FDA reviewer backs approval of TMC's cangrelor

Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the

Latest news

  • R&D productivity takes off R&D productivity takes off

    Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.

  • Merck's first-in-class Zontivity cleared in US Merck's first-in-class Zontivity cleared in US

    Merck's first-in-class Zontivity cleared in US. FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk. ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1 antagonist is also under regulatory

  • FDA panel backs Merck's vorapaxar FDA panel backs Merck's vorapaxar

    Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics